scholarly journals Clinical significance of Serum Pepsinogen I/II and gastrin-17 determination in gastric cancer diagnosis and prognosis

2018 ◽  
Vol 16 ◽  
pp. 205873921878129 ◽  
Author(s):  
Huiguang Xue ◽  
Aihua Yang ◽  
Fuguo Liu ◽  
Xueguo Sun ◽  
Xishuang Liu
Keyword(s):  
Gastric Cancer ◽  
Gastric Ulcer ◽  
Control Group ◽  
Serum Pepsinogen ◽  
Gastric Function ◽  
Pepsinogen I ◽  
Diagnosis And Prognosis ◽  
Cancer Group ◽  
Ulcer Group ◽  
Gastric Cancer Group

Currently, the diagnosis of atrophic gastritis and gastric cancer are mainly made by endoscopy and histopathology. Our study aimed to explore the practical value of Serum Pepsinogen I/II and gastrin-17 in gastric cancer diagnosis and prognosis. We collected 60 cases of gastric ulcer from February 2015 to November 2016 as gastric ulcer group, and 40 cases of gastric cancer treated in the same period as gastric cancer group. In 3  years after gastric cancer, 20 patients were served as postoperative gastric cancer group, and 70 healthy subjects as control group. The results showed that serum Pepsinogen I/II, gastrin-17, and other serum gastric function indexes were tested by enzyme-linked immunosorbent assay (ELISA). The serum PGI level of gastric ulcer group was higher than control group ( P  <  0.05). The serum G-17 concentrations in gastric ulcer group, gastric cancer group, and postoperative gastric cancer group were all higher than control group ( P  <  0.05). The area under receiver operating characteristic (ROC) curve of PGI screening was 0.905 and the best cutoff point was PGI  <  75  µg/L. Their sensitivity and specificity were 87.2% and 75.1%; the area under ROC curve of PGI/PGII rate screening was 0.761 and the best cutoff point was PGI/PGII  <  4. Their sensitivity and specificity were 88.9% and 62.3%. Multi logistical regression showed that the level of serum PGI, PGI, and G-17 and the odds ratio (OR) level of gastric cancer risk were 2.093, 2.653, and 0.494 ( P  <  0.05). The examination of Serum Pepsinogen I/II, gastrin-17, and other serum gastric function indexes can be used in the diagnosis and prognosis of gastric cancer and has a rather high practical value in monitoring recurrence in postoperative gastric cancer patients.

SERUM PEPSINOGEN I LEVELS IN GASTRIC CANCER

2013 ◽  
pp. 43-49
Author(s):  
Thi Minh Tam Phan ◽  
Thi Thu Huong Hoang ◽  
Anh Tuyen Nguyen ◽  
Thi Phuong Anh Le ◽  
Nguyen Tuong Van Ha
Keyword(s):  
Gastric Cancer ◽  
Predictive Value ◽  
Area Under The Curve ◽  
Control Group ◽  
Serum Pepsinogen ◽  
Pepsinogen I ◽  
Cancer Group ◽  
And Control ◽  
Group Serum ◽  
Gastric Cancer Group

Objective: Identification of serum Pepsinogen I levels in gastric cancer. Materials and Methods: Serum pepsinogen I levels was measured by enzym-linked immunosorbent assay (ELISA) on 32 patients in the gastric cancer group diagnosed by endoscopy and histology and control group of 30 patients with functional dyspepsia on endoscopy Using the cut-off value: PGI ≤ 70 ng/ml for gastric cancer. Results: Median Pepsinogen I levels in gastric cancer group was 41.07 ng / ml (25% quartile: 27.83 ng / ml, 75% quartile: 61.57 ng/ml) was significantly lower in control group: 102.03 ng / ml (25% quartile: 57.63 ng / ml, 75% quartile: 129.32 ng/ml) (p<0.001). The rate of Serum Pepsinogen I (≤ 70 ng/ml) was 78.1% in patients with gastric cancer, was 26.7% in the control group. Serum Pepsinogen I test in cut-off value ≤ 70 ng/ml had a sensitivity of 78.1%, specificity 73.3%, positive predictive value of 75.8% and the predictive value negative of 75.9% (p <0.001). The results of the ROC curve: area under the curve = 0.846,p <0.0001 at the cut-of of Pepsinogen I levels in our study ≤ 50.83 ng/ml with the optimal sensitivity and specificity were 65.6% and 86.7%. Key words: serum Pepsinogen I, gastric cancer

Identification of a high risk gastric cancer group using serum pepsinogen after successful eradication ofHelicobacter pylori

2012 ◽  
Vol 28 (1) ◽  
pp. 78-83 ◽  
Author(s):  
Masahira Haneda ◽  
Mototsugu Kato ◽  
Saori Ishigaki ◽  
Mio Suzuki ◽  
Masakazu Takahashi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
High Risk ◽  
Serum Pepsinogen ◽  
Cancer Group ◽  
Gastric Cancer Group

The effect of CTLA-4 and CD28 gene variants and circulating protein levels in patients with gastric cancer

2017 ◽  
Vol 42 (5) ◽  
Author(s):  
Soykan Arikan ◽  
Alper Gümüş ◽  
Özlem Küçükhüseyin ◽  
Cihan Coşkun ◽  
Saime Turan ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Control Group ◽  
Protein Levels ◽  
Cancer Group ◽  
Pcr Rflp ◽  
Gastric Cancer Patients ◽  
Turkish Patients ◽  
Circulating Levels ◽  
Gastric Cancer Group

AbstractObjective:Gastric cancer is one of the most common malignancies worldwide. The risk factors for gastric cancer include environmental and genetic factors. Inflammation and the immune system are known to contribute to the development of the gastric cancer. We examined the influence of critical polymorphisms of CTLA-4 and CD28 genes and circulating protein levels on the etiology of gastric cancer.Methods:Genotyping of SNPs was performed in 55 gastric cancer patients and 105 healthy individuals using the PCR-RFLP method, and circulating levels of sCTLA-4 and sCD28 were measured.Results:There were no significant differences in the genotype and allele distributions of the evaluated SNPs [CTLA-4-318 C>T (rs5742909), CTLA-4+49 A>G (rs231775), CD28 C>T (rs3116496)] between gastric cancer patients and controls (p=0.36, p=0.78, and p=0.80, respectively). The circulating levels of sCTLA-4 and sCD28 were significantly different between the gastric cancer group and the control group (p<0.001 and p<0.001, respectively).Conclusion:The present results suggest that the CTLA-4 and CD28 gene polymorphisms that were evaluated do not play an important role in Turkish patients with gastric cancer. However, sCTLA4 and sCD28 levels were higher in cancer patients and may be useful as an auxiliary parameter in the diagnosis and monitoring of gastric cancer.

scholarly journals Only serum pepsinogen I and pepsinogen I/II ratio are specific and sensitive biomarkers for screening of gastric cancer

2019 ◽  
Vol 10 (1) ◽  
pp. 82-90 ◽  
Author(s):  
Fariborz Mansour-Ghanaei ◽  
Farahnaz Joukar ◽  
Massood Baghaee ◽  
Masood Sepehrimanesh ◽  
Amineh Hojati
Keyword(s):  
Gastric Cancer ◽  
Plasma Levels ◽  
Serum Levels ◽  
Normal Weight ◽  
Control Group ◽  
Case Group ◽  
Serum Pepsinogen ◽  
Lower Plasma ◽  
Pepsinogen I ◽  
Pepsinogen Ii

AbstractPurposeWe aimed to determine optimal cut-off points of plasma levels of ghrelin and serum levels of pepsinogen I, II, and their ratio for screening of gastric cancer (GC).MethodsBlood samples were taken from 41 patients with confirmed gastric cancer along with 82 patients without malignancy. Serum levels of pepsinogen I and II, plus plasma levels of acylated ghrelin were measured using commercial ELISA kits.ResultsThe case group had significant lower plasma levels of ghrelin, pepsinogen I, and pepsinogen I/II ratio in comparison to the control group (P<0.001). In the control group, there was significant higher serum pepsinogen I (P=0.028) and pepsinogen II (P=0.003) and lower pepsinogen I/II ratio (P=0.020) in males versus females; significantly higher serum pepsinogen II (P=0.047) and lower pepsinogen I/II ratio (P=0.030) in overweight compared to normal weight patients; and significantly lower pepsinogen I/II ratio (P=0.030) in smokers versus non-smoker. In the case group, there was only significantly lower pepsinogen I (P=0.006) in males versus females, and significantly lower plasma ghrelin (P=0.017) in overweight compared to normal weight patients. The characteristic curve analysis indicated that pepsinogen I at a cut-off of 70.95 μg/L and pepsinogen I/II ratio at cut-off of 2.99, had good sensitivity and specificity.ConclusionsJust serums levels of pepsinogen I and the ratio of pepsinogen I/II can be used as biomarker to screen GC.

The expression levels of miR-655-3p, miR127-5p, miR-369-3p, miR-544a in gastric cancer

2019 ◽  
Vol 44 (4) ◽  
pp. 487-491 ◽  
Author(s):  
Hani Alsaadoni ◽  
Burcu Çaykara ◽  
Sadrettin Pençe ◽  
Halime Hanım Pençe ◽  
Süleyman Bademler
Keyword(s):  
Gastric Cancer ◽  
Genetic Factors ◽  
Fold Change ◽  
Control Group ◽  
Expression Levels ◽  
Cancer Group ◽  
Chromosome 14Q32 ◽  
Polymerase Chain ◽  
Gastric Cancer Group ◽  
Gene Expression Levels

Abstract Background Gastric cancer, one of the most common cancers in the world, is a multifactorial disease in which environmental and genetic factors play a role. In our study, we aimed to determine the expression levels of four miRNAs (miR127-5p, miR-544a, miR-369-3p and miR-655-3p) on chromosome 14q32 in gastric cancer. Materials and methods Total RNA was isolated from blood samples taken from 66 gastric cancer and 66 healthy individuals. The gene expression levels determined by cDNA and quantitative real-time polymerase chain reaction were analyzed according to the 2−∆∆Ct method. SPSS 22 were used for statistical analysis and p < 0.05 was considered as statistically significant. Results and discussion miR-655-3p (fold change: 100, p = 0.026), miR-127-5p (fold change: 48, p < 0.001) and miR-369-3p (fold change: 1.6, p > 0.05) was less expressed in the gastric cancer group than control group. miR-544a was found 15.5-fold more expressed in the patient group than control group (fold change: 15.47, p < 0.001). Conclusion miR127-5p, miR-544a, and miR-655-3p may be evaluated as biomarkers in gastric cancer.

Study on the Value of miR6503-5p Combined with PGR in the Diagnosis of Early Gastric Cancer

2021 ◽  
Vol 7 (5) ◽  
pp. 1516-1521
Author(s):  
Xuli Guo ◽  
Lezhong Yuan ◽  
Xia Yuan ◽  
Xiaohong Guo ◽  
Jun Li ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Early Gastric Cancer ◽  
Roc Curve ◽  
Serum Levels ◽  
Stage I ◽  
Stage Ii ◽  
Control Group ◽  
Cancer Group ◽  
Significant Difference ◽  
Gastric Cancer Group

Objective To investigate the value of serum miRNA 6503-5p (miR6503-5p) combined with pepsinogen ratio (PGR) in the diagnosis of early gastric cancer. Methods: 94 patients (gastric cancer group) with gastric cancer confirmed by pathological examination and 90 patients with chronic atrophic gastritis collected by Department of Pathology in our hospital were selected as the control group, the serum levels of pepsinogen (PG I, PG II) and miR6503-5p were measured in the two groups, and the value of the two indexes in the diagnosis of gastric cancer was analyzed by ROC. Results: The serum levels of miR6503-5p in gastric cancer group were significantly higher than those in control group (P<0.05), the serum levels of PG I and PGR in gastric cancer group were significantly lower than those in control group (P<0.05), the serum levels of miR6503-5p in stage II gastric cancer group were significantly higher than those in stage I patients with statistically significant difference (P<0.05), and the serum levels of PG I and PGR in stage II gastric cancer group were significantly lower than those in stage I patients with statistically significant difference (P<0.05). The serum levels of PG I, PG II and PGR in the patients with highly and moderately differentiated gastric cancer were not significantly different from those in the patients with poorly and undifferentiated gastric cancer, with no statistically significant different (P>0.05); the serum levels of miR6503-5p in the patients with highly and moderately differentiated gastric cancer were significantly lower than those in the patients with poorly and undifferentiated gastric cancer, with statistically significant difference (P<0.05); the sensitivity of miR6503-5p in diagnosing gastric cancer was 81.33%, the specificity was 71.09%, the area under the ROC curve was 0.767; the sensitivity of PGR in diagnosing gastric cancer was 85.81%, the specificity was 78.40%, and the area under the ROC curve was 0.827. The sensitivity of serum miR6503-5p combined with PGR was 96.40%, the specificity was 85.44%, and the area under the ROC curve was 0.920. Conclusion The miR 6503-5p combined with PGR has high sensitivity and specificity in the diagnosis of gastric cancer and is worthy of clinical application in the screenof patient with early gastric cancer.

Expression and Clinical Significance of Serum Exosomal miR-375 in Patients with Gastric Cancer

2021 ◽  
Vol 7 (5) ◽  
pp. 3896-3904
Author(s):  
Daoting Deng ◽  
Hong Zhang ◽  
Junxi Liu ◽  
Lina Ma ◽  
Xinrui Lei ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Cox Regression ◽  
Prognostic Significance ◽  
Cox Regression Analysis ◽  
Healthy Group ◽  
Cancer Group ◽  
Kaplan Meier ◽  
Gastric Cancer Patients ◽  
Gastric Cancer Group

To explore exosomal miR-375 expression in gastric cancer patients and its relationship with patient prognosis. A total of 53 patients diagnosed with gastric cancer in our hospital from May 2014 to May 2016 were included as the gastric cancer group, and 46 healthy women who came to our hospital for physical examination during the same period were enrolled as the healthy group. Exosomal miR-375 expression level was detected using qRT-PCR, and the diagnostic performance and prognostic significance of exosomal miR-375 in gastric cancer were explored. The gastric cancer group showed increased exosomal miR-375 expression than the healthy group (P< 0.05); Kaplan-Meier survival analysis exhibited that serum exosomal miR-375 has an AUC of 0.778, sensitivity of 69.57%, and specificity of 75.47%, whereas Cox regression analysis showed that the miR-375 expression in exosomes was an independent risk factor affecting the prognosis of gastric cancer patients (P< 0.05). Patient with gastric cancer showed upregulated miR-375 expression in serum exosomes. Serum exosomal miR-375 was found to has positive sensitivity and specificity in the diagnosis of gastric cancer, which may be associated with poor prognosis of gastric cancer patients.

Sign in / Sign up

Export Citation Format

Share Document